NCT03523572 2025-01-27Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial CancerDaiichi SankyoPhase 1 Completed86 enrolled 22 charts
NCT05824975 2024-11-25A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)GI Innovation, Inc.Phase 1/2 Recruiting358 enrolled